跳至主要内容
临床试验/EUCTR2015-005715-32-SE
EUCTR2015-005715-32-SE进行中(未招募)1 期

SOdium-glucose CO-transporter inhibition in patients with Type 2 Diabetes and Ischemic Heart Failure (SOCODIHF) - SOCODIHF

Karolinska Institutet Stockholm, Sweden0 个研究点目标入组 60 人开始时间: 2016年2月16日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Age = 18 years
  • 2. Known T2DM (according to current WHO criteria) with HbA1c 48-86 mmol/mol (DCCT 5.6-10%; [57]).
  • 3. Chronic HF of ischemic origin (established according to current European Guidelines; Ischemic etiology defined as history of myocardial infarction given by typical ECG-changes (Q-wave or LBBB), previous PCI or CABG, symptoms typical of angina pectoris with coronary artery disease verified by an exercise test, non-invasive imaging or coronary angiography, since at least two months [58].
  • 4. Signed informed consent to trial participation consistent with ICH-GCP guidelines and local legislations
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 50

排除标准

  • 1. Age > 75 years
  • 2. Contraindications to magnetic resonance imaging
  • a) Implanted devices such as pacemaker or implantable cardioverter defibrillator
  • b) Severe claustrophobia
  • 3. Serum creatinine estimated glomerular filtration rate < 30 ml/min/1.73m2
  • 4. Intolerance or contraindications to iv adenosine infusion, including clinically important asthma Patients with chronic obstructive pulmonary disease (COPD) should have a lung function test with reversibility testing performed within 12 month before study inclusion. The patient can be included if FEV1.0 is >60% of expected normal value and the reversibility test result should be <10% of the initial FEV1.0 value.
  • 5. Patients with severe concomitant disease (i.e. malignancy, liver failure) or chronic HF due to valvular disorders.
  • 6. Patients who, in the opinion of the investigator, will have difficulties to comply with the protocol (examples: problems to self-monitor glucose, linguistic problems, resident outside of the catchment area, alcohol or drug abuse, psychiatric disorder)
  • 7. Planned for intervention with at discharge are planned for Coronary Artery Bypass Grafting, Percutaneous Coronary Intervention or cardiac device treatment

研究者

发起方
Karolinska Institutet Stockholm, Sweden

相似试验